These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17223743)

  • 1. Alfimeprase: a novel recombinant direct-acting fibrinolytic.
    Deitcher SR; Funk WD; Buchanan J; Liu S; Levy MD; Toombs CF
    Expert Opin Biol Ther; 2006 Dec; 6(12):1361-9. PubMed ID: 17223743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis.
    Toombs CF
    Haemostasis; 2001; 31(3-6):141-7. PubMed ID: 11910179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-clinical and clinical characterization of a novel acting thrombolytic: alfimeprase.
    Deitcher SR; Toombs CF
    Pathophysiol Haemost Thromb; 2005; 34(4-5):215-20. PubMed ID: 16707931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alfimeprase.
    Drugs R D; 2008; 9(3):185-90. PubMed ID: 18457471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrolase: trials and tribulations.
    Markland FS; Swenson S
    Toxins (Basel); 2010 Apr; 2(4):793-808. PubMed ID: 22069611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug evaluation: alfimeprase, a plasminogen-independent thrombolytic.
    Shah AR; Scher L
    IDrugs; 2007 May; 10(5):329-35. PubMed ID: 17487785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices.
    Moll S; Kenyon P; Bertoli L; De Maio J; Homesley H; Deitcher SR
    J Clin Oncol; 2006 Jul; 24(19):3056-60. PubMed ID: 16809729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs. alfimeprase.
    Hong TT; Huang J; Lucchesi BR
    Am J Physiol Heart Circ Physiol; 2006 Mar; 290(3):H959-67. PubMed ID: 16243915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR; Collen D
    Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hirudin and s18886 maintain luminal patency after thrombolysis with alfimeprase.
    Lee JY; Markland FS; Lucchesi BR
    J Cardiovasc Pharmacol; 2013 Feb; 61(2):152-9. PubMed ID: 23188127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemorrhagic profile of the fibrinolytic alfimeprase after ischemia and reperfusion.
    Lu A; Kurosawa Y; Luskey K; Pyne-Geithman G; Caudell D; Clark J
    Neurol Res; 2009 Mar; 31(2):209-14. PubMed ID: 19298764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of alfimeprase for peripheral arterial thrombolysis.
    Ouriel K; Cynamon J; Weaver FA; Dardik H; Akers D; Blebea J; Gruneiro L; Toombs CF; Wang-Clow F; Mohler M; Pena L; Wan CY; Deitcher SR
    J Vasc Interv Radiol; 2005 Aug; 16(8):1075-83. PubMed ID: 16105919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential.
    Marder VJ; Novokhatny V
    J Thromb Haemost; 2010 Mar; 8(3):433-44. PubMed ID: 19943877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New directions in thrombolytic therapy.
    Toombs CF
    Curr Opin Pharmacol; 2001 Apr; 1(2):164-8. PubMed ID: 11714091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer thrombolytic drugs for acute myocardial infarction.
    Reddy DS
    Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alfimeprase for the treatment of acute peripheral arterial occlusion.
    Moise MA; Kashyap VS
    Expert Opin Biol Ther; 2008 May; 8(5):683-9. PubMed ID: 18407770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Staphylokinase--a specific plasminogen activator].
    Rozpończyk E; Szemraj J; Malinowski M; Rozpończyk J
    Postepy Biochem; 2006; 52(1):80-6. PubMed ID: 16869305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alfimeprase to succeed Genentech's alteplase?
    Vastag B
    Nat Biotechnol; 2006 Aug; 24(8):875-6. PubMed ID: 16900112
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Davidson DJ; Lubbers NL; Reininger IM; Henkin J
    Thromb Res; 1996 Sep; 83(6):421-31. PubMed ID: 8885137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel thrombolytic agents.
    Verstraete M; Lijnen HR
    Cardiovasc Drugs Ther; 1994 Dec; 8(6):801-11. PubMed ID: 7742258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.